The Association of the British Pharmaceutical Industry (ABPI) is to review both the Code of Practice for the UK pharma industry and the body that administers it.
Chief executive Stephen Whitehead said the review aims to ensure that the code continues to “'address all issues in the environment and the changing role of external stakeholders”.
The board hopes to recommend changes for inclusion in a new code that will be published January 1, 2015. Any planned changes will be subject to the usual consultation and would need to be agreed at the ABPI members' meeting held November 2014.
Additional to this review, the implementation of the EFPIA Disclosure Code, which covers certain payments to healthcare professionals and healthcare organisations, is ongoing. New ABPI guidance to reflect this will be dated January 1, 2014, with a transition period.
Commenting on the review, Whitehead mentioned the Code's need to be flexible in order to respond to changing external requirements such as major NHS reforms, the growing influence of public health bodies and the increasing weight of health technology assessment (HTA) in the UK.
“The review is an important step in ensuring that the industry has clear guidance for interactions and partnership at a time when the UK environment is changing significantly. It will ensure that the industry is in the best possible position to deal with the new environment it faces,” he said.
The ABPI code reflects UK and European law, EFPIA and IFPMA codes, in addition to UK-specific requirements. All members of the ABPI and EFPIA are covered by the code, as are a number of non-member companies that have agreed to comply with it.